GSK and Genmab submit ofatumumab application to FDA

March 2009
Hem/Onc Today;3/10/2009, Vol. 10 Issue 5, p49
The article reports on the submission of a Biologics License Application to the U.S. Food and Drug Administratino (FDA) by GlaxoSmithKline and Genmab.


Related Articles

  • Genmab Boosts Balance Sheet via Retooled GSK Collaboration.  // BioWorld Today;7/2/2010, Vol. 21 Issue 127, p4 

    The article reports on the restructuring of the agreement between Genmab A/S and GlaxoSmithKline plc. In 2006, Genmab licensed rights to then-Phase III-stage anti-CD20 antibody ofatumumab to GlaxoSmithKline (GSK). The 250 million U.S. dollar worth of manufacturing facility purchased by Genmab...

  • Genmab, GSK Move Into Phase III With Ofatumumab In Europe. Sheridan, Cormac // BioWorld International;11/21/2007, Vol. 12 Issue 47, p1 

    The article reports on the Phase III program being started by Genmab A/S and GlaxoSmithKline plc for ofatumumab in the treatment of rheumatoid arthritis in Europe. U.S. studies are slated for 2008. An analyst at the Copenhagen, Denmark office of Enskilda Bank, Peter Sehested, said that he was a...

  • Genmab and GSK initiate Phase III program of rheumatoid arthritis.  // PharmaWatch: Biotechnology;Jan2008, Vol. 7 Issue 1, p6 

    The article focuses on the plan of Genmab and GlaxoSmithKline (GSK) to establish a Phase III program with Ofatumumab, a drug used for the treatment of rheumatoid arthritis. The program is expected to commence in two patient populations. The first study will be for those who have had an unequal...

  • Earnings Roundup.  // BioWorld Today;10/24/2013, Vol. 24 Issue 205, p9 

    The article reports that Genmab A/S and Glaxosmithkline PLC posted worldwide sales of Arzerra, a chronic lymphocytic leukemia drug, for the third quarter of 2013.

  • Genmab/GlaxoSmithKline: Arzerra suffers study setback.  // PharmaWatch: Cancer;Oct2009, Vol. 8 Issue 10, p4 

    The article reports on the decision of Genmab A/S and GlaxoSmithKline to stop their study on Arzerra after the phase III trial failed to reach the endpoint in patients with refractory non-Hodgkin's lymphoma (NHL) in the U.S. As a result, the Genmab will no longer receive payment from its...

  • Genmab's Upbeat following Changes and Restructuring. Moran, Nuala // BioWorld International;1/26/2011, Vol. 16 Issue 6, p1 

    This article reports on the decision of biotechnology company Genmab A/S renegotiate a partnership with GlaxoSmithKline PLC for the marketed anti-CD20 antibody Arzerra. According to Genmab chief executive officer (CEO) Jan van de Winkel, the company is well funded with oncology pipeline and a...

  • Flurry of Antibody M&A, but Genmab Left Out in the Cold. Boggs, Jennifer // BioWorld Insight;7/12/2010, Vol. 18 Issue 28, p2 

    The article reports that the Phase II clinical trial for Genmab A/S's anti-CD20 candidate ofatumumab has scored a positive hit for multiple sclerosis. However, its clinical success can unlikely impact the firm's restructured deal with GlaxoSmithKline which planned to eliminate future milestones...

  • Blockbuster MAbs Fueling Big Deals. Flanagan, Nina // Pharma DD: Tracking Discovery & Development;Jan/Feb2007, Vol. 2 Issue 1, p40 

    The article reports on mergers and acquisitions within the pharmaceutical industry caused by the success of monoclonal antibodies (mAb)-based therapeutics. One is the $2.1 billion development and marketing deal signed by GSK with Genmab for its HuMax-CD20 antibody. Another trend in the mAb...

  • GSK and Genmab file biologics license application for leukemia drug.  // PharmaWatch: Cancer;Mar2009, Vol. 8 Issue 3, p8 

    The article reports on the submission of a biologics license application by GlaxoSmithKline (GSK) and Genmab A/S for the leukemia drug Arzerra, also known as ofatumumab, to the U.S. Food and Drug Administration. It explains the implication of the move as well as provides an overview of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics